@article {1304386,
	title = {Management of Ocular Cicatricial Pemphigoid with Intravenous Immunoglobulin Monotherapy},
	journal = {Ocul Immunol Inflamm},
	year = {2018},
	month = {2018 Mar 08},
	pages = {1-7},
	abstract = {PURPOSE: To assess the long-term efficacy and safety of IVIg monotherapy in patients with recalcitrant ocular cicatricial pemphigoid (OCP). METHODS: A chart review of all OCP patients seen at the Massachusetts Eye Research and Surgery Institution (MERSI) between 2005 and 2015 was completed. Stage was graded by using the Foster grading system. IVIg infusion was 2g/kg/cycle administered in 3 consecutive days monthly. RESULTS: Of 512 OCP patients, 17 patients (34 eyes) treated with IVIg monotherapy were identified. Seven were female and ten were male. The average age at diagnosis was 60.7-year-old. The follow up time ranged from 12 to 140 months. Twenty-six eyes (76.5\%) achieved remission. Nine remission eyes received cataract surgeries, and 2 of them had relapse (22.2\%). The other 17 eyes did not undergo ocular surgery and remained in remission. IVIg monotherapy showed high efficacy in stage 1 OCP (7/7, 100\%). Ocular surgery can be associated with OCP relapse (Table 2). CONCLUSIONS: IVIg monotherapy is an effective and safe therapy in patients with recalcitrant OCP. Ocular surgery can be associated with OCP relapse.},
	issn = {1744-5078},
	doi = {10.1080/09273948.2018.1433302},
	author = {Ma, Lina and You, Caiyun and Hernandez, Mikhail and Maleki, Arash and Lasave, Andres and Schmidt, Alexander and Stephenson, Andrew and Zhao, Thongzen and Anesi, Stephen and Foster, C Stephen}
}
